

**PCR-/NAT *Chlamydia trachomatis*
 (RV 531) November 2011**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.
Sample composition and expected results.

| | <i>Erwartet / expected</i> | | <i>Probenzusammensetzung / Sample composition</i> |
|---------|----------------------------|----|---|
| 1125311 | + | 61 | <i>Chlamydia trachomatis</i> (~ 1x10 ³ IFU/mL) |
| 1125312 | + | 61 | <i>Chlamydia trachomatis</i> (~ 1x10 ³ IFU/mL) |
| 1125313 | ∅ | 62 | <i>Escherichia coli</i> K12 |
| 1125314 | ∅ | 62 | <i>Escherichia coli</i> K12 |

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.
Absolute numbers of reported individual results.

| <i>n = 121</i> | <i>Probennummer (Sample no.)</i> | | | | | <i>Inhibition</i> | | | |
|--|----------------------------------|----------------|----------------|----------------|-------------------|-------------------|----------------|----------------|----------------|
| | <i>1125311</i> | <i>1125312</i> | <i>1125313</i> | <i>1125314</i> | | <i>1125311</i> | <i>1125312</i> | <i>1125313</i> | <i>1125314</i> |
| Befund <i>Result</i> | | | | | | | | | |
| Positiv | 120 | 115 | 0 | 1 | n.d. | 0 | 0 | 0 | 0 |
| Negativ | 1 | 5 | 121 | 120 | nein <i>no</i> | 121 | 121 | 121 | 121 |
| Fraglich <i>Questionable</i> | 0 | 1 | 0 | 0 | ja <i>yes</i> | 0 | 0 | 0 | 0 |

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

| NAT-Methode [Code] (total number *) | NAT richtig positiv <i>True positive results</i> | | | NAT richtig negativ <i>True negative results</i> | | |
|---|--|-----------------------------------|------------|--|-----------------------------------|------------|
| | Absolut <i>Absolute</i> | Relativ <i>Relative</i> | % | Absolut <i>Absolute</i> | Relativ <i>Relative</i> | % |
| GenoQuick CT (Hain) [20] (n = 24) | 46 | 46 / 48 | 96 | 46 | 46 / 46 | 100 |
| LightMix CT [21] (n = 2) | 3 | 3 / 4 | 75 | 4 | 4 / 4 | 100 |
| Roche COBAS TaqMan [22] (n = 32) | 64 | 64 / 64 | 100 | 63 | 63 / 64 | 98 |
| COBAS AmpliCor [23] (n = 3) | 6 | 6 / 6 | 100 | 6 | 6 / 6 | 100 |
| BD ProbeTec [24] (n = 16) | 32 | 32 / 32 | 100 | 32 | 32 / 32 | 100 |
| Artus CT [25] (n = 9) | 17 | 17 / 17 [§] | 100 | 18 | 18 / 18 | 100 |
| Abbott CT/NG [26] (n = 4) | 8 | 8 / 8 | 100 | 8 | 8 / 8 | 100 |
| Other commercial tests [27] (n = 19) | 38 | 38 / 38 | 100 | 38 | 38 / 38 | 100 |
| In house PCR assay [28] (n = 13) | 23 | 23 / 26 | 88 | 26 | 26 / 26 | 100 |

* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.
 Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants.

[§] Due to reporting questionable results, the number of true results (denominator in the "relative" column) have been reduced.